Abstract
The paper presents the results of an open-label nonrandomized prospective trial, the purpose of which was to evaluate the efficiency and safety of etanercept (ETC) treatment for different forms and variants of active juvenile idiopathic arthritis (JIA) in real clinical practice. The trial included 24 patients with JIA. ETC treatment proved to be effective in most patients with a long disease history and a high clinical and laboratory activity who were refractory to conventional antirheumatic therapy. ETC therapy was most effective in patients with the articular form of the disease who showed 100% improvement in at least ACRpedi30 criteria at 6 months of treatment.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
